Reduced Foxp3 protein expression is associated with inflammatory disease during human T lymphotropic virus type 1 infection

Journal of Infectious Diseases

Volumn 193, Issue 11, 2006, Pages 1557-1566

  Oh, Unsong ^a   Grant, Christian ^a   Griffith, Caitlin ^a   Fugo, Kazunori ^a   Takenouchi, Norihiro ^a   Jacobson, Steven ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INFLAMMATORY DISEASE; LEUKOCYTE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; VIRUS CARRIER; VIRUS LOAD;

ANTIGENS, CD27; ANTIGENS, CD4; DNA, VIRAL; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENES, PX; HTLV-I INFECTIONS; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; RECEPTORS, INTERLEUKIN-2; STATISTICS; T-LYMPHOCYTES, REGULATORY; VIRAL LOAD;

EID: 33646906178     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/503874     Document Type: Article

References (29)

1. + T cells with regulatory properties from human blood. J Exp Med 2001; 193:1303-10.
2. + T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193:1285-94.
3. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188:287-96.
4. + suppressor T cells. J Exp Med 2001; 193:F41-6.
5. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-62.
6. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-53.
7. + T cells. Clin Immunol 2005; 115:10-8.
8. Yagi H, Nomura T, Nakamura K, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004; 16:1643-56.
9. Ruprecht CR, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005; 201:1793-803.
10. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
11. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20-1.
12. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6:331-7.
13. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:971-9.
14. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005; 102:6449-54.
15. Huan J, Culbertson N, Spencer L, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005; 81:45-52.
16. de Kleer IM, Wedderburn LR, Taams LS, et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004; 172:6435-43.
17. + T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest 2005; 115:1361-8.
18. Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1989; 1:441.
19. Zucker-Franklin D. Non-HIV retroviral associations with rheumatic disease. Curr Rheumatol Rep 2000; 2:156-62.
20. Yoshimura K, Mochizuki M, Araki S, et al. Clinical and immunologic features of human T-cell lymphotropic virus type I uveitis. Am J Ophthalmol 1993; 116:156-63.
21. Watanabe T. HTLV-1-associated diseases. Int J Hematol 1997; 66:257-78.
22. Jacobson S, Zaninovic V, Mora C, et al. Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann Neurol 1988; 23(Suppl): S196-200.
23. + T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 2002; 99:88-94.
24. Miura T, Yokoyama H, Minegishi N, Sasaki T, Kaku M, Harigae H. Flow cytometry of GATA transcription factors. Cytometry B Clin Cytom 2003; 56:1-7.
25. + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005; 105:735-41.
26. + T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001; 31:1122-31.
27. Orland JR, Engstrom J, Fridey J, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology 2003; 61:1588-94.
28. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4:586-93.
29. Jeffery KJ, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999; 96:3848-53.